Validation of the PANAMA-Score for Survival and Benefit of Adjuvant Therapy in Patients with Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX

医学 叶黄素 胰腺癌 新辅助治疗 肿瘤科 胰腺切除术 内科学 辅助治疗 佐剂 癌症 外科 伊立替康 胰腺 结直肠癌 乳腺癌
作者
Ingmar F. Rompen,Thomas F. Stoop,Stijn van Roessel,Eran van Veldhuisen,Quisette P. Janssen,Adnan Alseidi,Alberto Balduzzi,Gianpaolo Balzano,Frederik Berrevoet,Morgan Bonds,Olivier R. Busch,Giovanni Butturini,Ammar A. Javed,Marco Del Chiaro,Kevin C. Conlon,Massimo Falconi,Isabella Frigerio,Giuseppe Fusai,Johan Gagnière,Oonagh Griffin
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
标识
DOI:10.1097/sla.0000000000006650
摘要

To validate the prognostic value of the PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection of pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant FOLFIRINOX. The PANAMA-score was developed to guide prognostication in patients after neoadjuvant therapy and resection for PDAC. As this score focuses on the risk for residual disease after resection, it might also be able to select patients who benefit from adjuvant after neoadjuvant therapy. This retrospective international multicenter study is endorsed by the European-African Hepato-Pancreato-Biliary Association (E-AHPBA). Patients with PDAC who underwent resection after neoadjuvant FOLFIRINOX were included. Mantel-Cox regression with interaction analysis was performed to assess the impact of adjuvant chemotherapy. Overall, 383 patients after resection of PDAC following neoadjuvant FOLFIRINOX were included of whom 187 (49%), 137 (36%), and 59 (15%) had a low-risk, intermediate-risk, and high-risk PANAMA-score, respectively. A discrimination in median OS was observed stratified by risk groups (48.5, 27.6, and 22.3 months, Log-Rank-Plow-intermediate=0.004, Log-Rank-Pintermediate-high=0.027). Adjuvant therapy was not associated with an OS difference in the low-risk group (HR 1.50, 95%CI:0.92-2.50), whereas improved OS was observed in the intermediate (HR 0.58, 95%CI:0.34-0.97) and high-risk groups (HR 0.47, 95%CI:0.24-0.94) (p-interaction=0.008). The PANAMA 3-tier risk groups (low-risk, intermediate-risk, and high-risk, available via pancreascalculator.com) correspond with differential survival in patients with resected PDAC following neoadjuvant FOLFIRINOX. The risk groups also differentiate between survival benefit associated with adjuvant treatment, with only the intermediate- and high-risk groups associated with improved OS.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zxy关闭了zxy文献求助
1秒前
2秒前
汪汪发布了新的文献求助10
2秒前
彭于晏应助痴情的飞薇采纳,获得10
2秒前
2秒前
yangfan发布了新的文献求助10
2秒前
3秒前
ZX完成签到,获得积分10
3秒前
3秒前
3秒前
丘比特应助堇言采纳,获得10
4秒前
SciGPT应助十一采纳,获得10
6秒前
6秒前
ZX发布了新的文献求助10
7秒前
英俊的铭应助yangfan采纳,获得10
7秒前
符氏子发布了新的文献求助10
7秒前
青芒发布了新的文献求助10
7秒前
7秒前
7秒前
696发布了新的文献求助10
7秒前
glory0510完成签到,获得积分10
8秒前
ZJH完成签到 ,获得积分10
8秒前
9秒前
FashionBoy应助活力的流沙采纳,获得10
9秒前
10秒前
11秒前
慈祥的夜安应助chenchen采纳,获得10
11秒前
11发布了新的文献求助10
12秒前
宝儿柯察金完成签到,获得积分10
12秒前
12秒前
Yong发布了新的文献求助10
13秒前
哒哒完成签到 ,获得积分10
15秒前
Jasper应助十一采纳,获得10
15秒前
林奇完成签到,获得积分10
15秒前
羊咩咩发布了新的文献求助10
16秒前
16秒前
杀手小鸡发布了新的文献求助10
16秒前
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Kinesiophobia : a new view of chronic pain behavior 3000
Les Mantodea de guyane 2500
Feldspar inclusion dating of ceramics and burnt stones 1000
What is the Future of Psychotherapy in a Digital Age? 801
The Psychological Quest for Meaning 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5963362
求助须知:如何正确求助?哪些是违规求助? 7223422
关于积分的说明 15966355
捐赠科研通 5099735
什么是DOI,文献DOI怎么找? 2739858
邀请新用户注册赠送积分活动 1702611
关于科研通互助平台的介绍 1619349